TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease

Nicola J. Rutherford; Minerva M. Carrasquillo; Ma Li; Gina Bisceglio; Joshua Menke; Keith A. Josephs; Joseph E. Parisi; Ronald C. Petersen; Neill R. Graff-Radford; Steven G. Younkin; Dennis W. Dickson; Rosa Rademakers

doi:10.1212/WNL.0b013e318264e3ac

TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease

Nicola J. Rutherford, Minerva M. Carrasquillo, Ma Li, Gina Bisceglio, Joshua Menke, Keith A. Josephs, Joseph E. Parisi, Ronald C. Petersen, Neill R. Graff-Radford, Steven G. Younkin, Dennis W. Dickson, Rosa Rademakers

Research output: Contribution to journal › Comment/debate › peer-review

53 Scopus citations

Original language	English (US)
Pages (from-to)	717-718
Number of pages	2
Journal	Neurology
Volume	79
Issue number	7
DOIs	https://doi.org/10.1212/WNL.0b013e318264e3ac
State	Published - Aug 14 2012

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e318264e3ac

Cite this

@article{064aad50d85c4658a98915097c9f4e01,

title = "TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease",

author = "Rutherford, {Nicola J.} and Carrasquillo, {Minerva M.} and Ma Li and Gina Bisceglio and Joshua Menke and Josephs, {Keith A.} and Parisi, {Joseph E.} and Petersen, {Ronald C.} and Graff-Radford, {Neill R.} and Younkin, {Steven G.} and Dickson, {Dennis W.} and Rosa Rademakers",

note = "Funding Information: Study funding: Supported by the National Institute of Health grant P50 AG16574 (to R.C.P., D.W.D., N.R.G.-R., and R.R.), R01 NS065782 (to R.R.), R01 AG26251 (to R.R.), R01 AG 037491 (to K.J.) , and the Consortium for frontotemporal dementia (to R.R.). Funding Information: Disclosure: N. Rutherford, M. Carrasquillo, M. Li, G. Bisceglio, and J. Menke report no disclosures. K. Josephs receives research support from the NIH and The Dana Foundation. J. Parisi serves as a Section Editor for Neurology{\textregistered} and receives research support from the NIH. R. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth, Pharmaceuticals, and GE Healthcare, and receives research support from the NIH. N. Graff-Radford serves on a scientific advisory board for Codman and receives research support from Pfizer, Elan Corporation, Forest Laboratories, Inc., Medivation, Inc. Janssen, Allon, and the NIH. S. Younkin receives research support from NIH and the Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. D. Dickson receives research support from the NIH, CurePSP and the State of Florida Department of Elder Affairs Alzheimer Disease Initiative. R. Rademakers receives research support from the NIH, the ALS Association, the ALS Therapy Alliance, CurePSP, and the Consortium for Frontotemporal Degeneration Research. Go to Neurology.org for full disclosures . ",

year = "2012",

month = aug,

day = "14",

doi = "10.1212/WNL.0b013e318264e3ac",

language = "English (US)",

volume = "79",

pages = "717--718",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease

AU - Rutherford, Nicola J.

AU - Carrasquillo, Minerva M.

AU - Li, Ma

AU - Bisceglio, Gina

AU - Menke, Joshua

AU - Josephs, Keith A.

AU - Parisi, Joseph E.

AU - Petersen, Ronald C.

AU - Graff-Radford, Neill R.

AU - Younkin, Steven G.

AU - Dickson, Dennis W.

AU - Rademakers, Rosa

N1 - Funding Information: Study funding: Supported by the National Institute of Health grant P50 AG16574 (to R.C.P., D.W.D., N.R.G.-R., and R.R.), R01 NS065782 (to R.R.), R01 AG26251 (to R.R.), R01 AG 037491 (to K.J.) , and the Consortium for frontotemporal dementia (to R.R.). Funding Information: Disclosure: N. Rutherford, M. Carrasquillo, M. Li, G. Bisceglio, and J. Menke report no disclosures. K. Josephs receives research support from the NIH and The Dana Foundation. J. Parisi serves as a Section Editor for Neurology® and receives research support from the NIH. R. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth, Pharmaceuticals, and GE Healthcare, and receives research support from the NIH. N. Graff-Radford serves on a scientific advisory board for Codman and receives research support from Pfizer, Elan Corporation, Forest Laboratories, Inc., Medivation, Inc. Janssen, Allon, and the NIH. S. Younkin receives research support from NIH and the Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. D. Dickson receives research support from the NIH, CurePSP and the State of Florida Department of Elder Affairs Alzheimer Disease Initiative. R. Rademakers receives research support from the NIH, the ALS Association, the ALS Therapy Alliance, CurePSP, and the Consortium for Frontotemporal Degeneration Research. Go to Neurology.org for full disclosures .

PY - 2012/8/14

Y1 - 2012/8/14

UR - http://www.scopus.com/inward/record.url?scp=84866102266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866102266&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318264e3ac

DO - 10.1212/WNL.0b013e318264e3ac

M3 - Comment/debate

C2 - 22855871

AN - SCOPUS:84866102266

SN - 0028-3878

VL - 79

SP - 717

EP - 718

JO - Neurology

JF - Neurology

IS - 7

ER -

TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this